Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 274,161 | 232,185 | 170,084 | 211,104 |
| Short-term investments | 196,277 | 228,753 | 327,750 | 387,645 |
| Restricted cash and cash equivalents, current | 1,925 | 1,922 | 2,215 | 88,218 |
| Equity investments | 5,861 | 6,077 | 8,679 | 7,270 |
| Prepaid expenses and other current assets | 44,761 | 45,143 | 36,956 | 41,469 |
| Total current assets | 522,985 | 514,080 | 545,684 | 735,706 |
| Intangible assets, net | 7,777 | 7,850 | 7,924 | 7,998 |
| Goodwill | 16,937 | 16,937 | 16,937 | 16,937 |
| Property and equipment, net | 53,158 | 55,620 | 58,203 | 60,795 |
| Operating right-of-use assets | 60,760 | 62,099 | 63,555 | 64,853 |
| Restricted cash and cash equivalents, noncurrent | 6,956 | 6,963 | 6,957 | 6,956 |
| Long-term investments | 332,970 | 314,575 | 304,212 | 286,099 |
| Other assets | 24,042 | 24,699 | 15,981 | 13,188 |
| Total assets | 1,025,585 | 1,002,823 | 1,019,453 | 1,192,532 |
| Deferred revenue, current | NaN | NaN | 0 | 10,109 |
| Contingent consideration obligation, current | NaN | 0 | 0 | 0 |
| Accounts payable | 5,445 | 9,803 | 6,847 | 12,234 |
| Accrued and other liabilities | 68,113 | 83,012 | 68,375 | 82,661 |
| Total current liabilities | 73,558 | 92,815 | 75,222 | 105,004 |
| Deferred revenue, noncurrent | NaN | NaN | 9,433 | NaN |
| Operating lease liabilities, noncurrent | 86,635 | 89,054 | 91,215 | 93,405 |
| Contingent consideration obligation, noncurrent | 33,210 | 34,100 | 34,180 | 33,620 |
| Other long-term liabilities | 19,417 | 21,578 | 13,305 | 13,031 |
| Total liabilities | 212,820 | 237,547 | 223,355 | 245,060 |
| Common stock, 0.0001 par value 300,000,000 shares authorized as of march31, 2026 and december31, 2025 161,234,058 and 139,474,954 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 16 | 14 | 14 | 14 |
| Additional paid-in capital | 2,139,698 | 1,965,090 | 1,952,843 | 1,941,386 |
| Accumulated other comprehensive loss | -3,483 | -2,057 | -1,911 | -2,221 |
| Accumulated deficit | -1,323,466 | -1,197,771 | -1,154,848 | -991,707 |
| Total stockholders equity | 812,765 | 765,276 | 796,098 | 947,472 |
| Total liabilities and stockholders equity | 1,025,585 | 1,002,823 | 1,019,453 | 1,192,532 |